Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Investor Presentation (December 2024)
34 slides from Anatara Lifesciences's investor presentation, Dec 2, 2024
Slide 1: Investor Presentation
For personal use only Investor Presentation ANATARA LIFESCIENCES LTD DECEMBER 2024
Slide 2: Disclaimer
ANATARA LIFESCIENCES Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara L
Slide 3: Investment Highlights
Investment Highlights Corporate Snapshot Novel Technology • Gastrointestinal Reprogramming (GaRP) technology aimed at restoring and maintaining the DEVELOPING EVIDENCED-BASED SOLUTIONS FOR GIT lining, integrity and homeostasis. GASTROINTESTINAL TRACT HEALTH ISSUES Pivotal Phase II clinical trial – I
Slide 4: Key Management & Board of Directors
Key Management Anatara’s nimble Board and Management structure provides significant & Board of Directors experience and flexibility for potential corporate transactions. HIGHLY EXPERIENCED BOARD & MANAGEMENT For personal use only Dr David Brookes John Michailidis Nicholas Haslam Executive Chair Exec
Slide 5: Gastrointestinal Health
Gastrointestinal Health ANATARA HAS ACTIVE PROGRAMS APPROACHING COMMERCIAL OUTCOMES Gastrointestinal RePrograming (GaRP) GaRP is a multi-component, multi-coated patented For personal use only complementary medicine. It is designed to address the underlying factors associated with chronic gastrointes
Slide 6: GaRP: One product, multiple benefits
GaRP Bromelain Reduces pro-inflammatory cytokines & serotonin; promotes healing via mucin ONE PRODUCT, MULTIPLE BENEFITS genes;reduces attachment some bacteria. Patent Protected Scientifically designed for the relief and management of Menthol background IBS symptoms and the rejuvenation of GIT dynam
Slide 7: Snapshot: IBS and IBD
Snapshot: IBS and IBD GASTROINTESTINAL DISORDERS ARE HIGHLY PREVALENT AND POORLY MANAGED 11% +5 million IBS affects 11% of IBD affects more than 5 million people For personal use only the global population 1 globally, with accelerating incidence 2 Debilitating Symptoms Patients seek alternative opti
Slide 8: IBS in America Survey
IBS in America Survey GaRP USE OF TREATMENTS FOR IRRITABLE BOWEL SYNDROME AND PATIENT SATISFACTION, BASED ON IBS IN AMERICA SURVEY The publication Significant “Highlights the opportunity for an need for further effective, Trial Details effective IBS evidenced based For personal use only Use and sati
Slide 9: Active Program – Phase II Clinical Trial
Active Program – Phase II Gastrointestinal RePrograming (GaRP) technology for ‘gut health’ Clinical Trial Active pivotal clinical trial – Irritable Bowel Syndrome: • Primary Endpoint – Efficacy of ‘GaRP’ for irritable bowel syndrome. STAGE 2 OF PHASE II CLINICAL TRIAL • 120-140 patient (inc Stage 1
Slide 10: Stage 2 Actively Recruiting
Stage 2 Actively Recruiting STAGE 2 OF THE PHASE 2 CLINICAL TRIAL Gastrointestinal RePrograming (GaRP) technology for ‘gut health’ PROGRESSING WELL Active pivotal clinical trial – Irritable Bowel Syndrome: • Actively recruiting for Stage 2. • 50 participants of target 60-100 enrolled. • Stage 2 – He
Slide 11: Clinical Trial - Irritable Bowel Syndrome
Clinical Trial - Irritable Bowel Syndrome ROBUST CLINICAL TRIAL TO VALIDATE THE EFFICACY OF GARP Title Dose Determination and Efficacy Evaluation of the Endpoints For personal use only Gastrointestinal ReProgramming (GaRP) dietary ✓ No Treatment-Related Adverse Events. supplement in IBS patients: A
Slide 12: GaRP - Grounded in scientific evidence
GaRP - Grounded in scientific evidence GARP ADDRESSES THE UNDERLYING FACTORS OF GASTROINTESTINAL DISORDERS For personal use only Diseased gut GaRP gut repair in action GaRP regenerated gut INVESTOR PRESENTATION ANATARA LIFESCIENCES Leaky ‘tight junctions’ allow pathogens to Increase in mucin gene ex
Slide 13: Clinical Trial Results
Median IBS-SSS Score – Baseline to week 8 Stage 1 Placebo Low Dose High Dose Clinical Trial Results Baseline n=20 265 n=20 240 n=21 280 Week 1 240 210 255 DELIVERED POSITIVE PRIMARY ENDPOINTS Week 2 195 145 180 Week 4 185 110 160 Stage 1 IBS Clinical Trial Week 6 220 100 140 • Number of Patients: Pl
Slide 14: Clinical Trial Results: Secondary Endpoints
TOTAL SCORE – Hospital Anxiety & Depression Score (HADS) Stage 1 Placebo Low Dose High Dose Clinical Trial Results Baseline N=20 11.6 N=20 13.3 N=21 14.2 Week 8/9 14 9.6 13.9 DELIVERED POSITIVE SECONDARY ENDPOINTS Week 10/11 13.5 9.2 15.2 Change from Baseline 3.5 -4.0 -0.7 Versus Placebo -6.0 (P<0.0
Slide 15: Gastrointestinal RePrograming (GaRP)
Gastrointestinal RePrograming (GaRP) A POTENTIAL BREAKTHROUGH FOR GUT HEALTH For personal use only Unique knowledge of Ingredients Well-characterised Potential Gut-Brain bromelain’s ‘fingerprint’ are GRAS proprietary formula synergistic effects Connection FUNCTION WITHIN FORMULATION AND POTENTIAL IM
Slide 16: Focused on developing a clinically validated treatment
Focused on developing a clinically validated treatment MAJOR GUT HEALTH TREATMENTS LACK CLINICAL EVIDENCE Evidenced Improvement Improving Improving IBS- Explanation Based Claims in IBS-SSS /or Anxiety & QOL Quality of Comments/Key Claims Rome II/III Depression Life Clinically meaningful improvement
Slide 17: Market Opportunity
Market Opportunity U.S. Digestive Health Products Market Size, by ingredient, 2020-2030 (USD Billion) THE GUT HEALTH MARKET IS SIGNIFICANT, LACKING EFFECTIVE, EVIDENCE-BASED SOLUTIONS Digestive Health Market to be valued at US$23.4B in 2030 8.1% U.S. Market CAGR, 2020 - $23.4B For personal use only
Slide 18: Gastrointestinal Market Opportunity
Market Opportunity Align® Proctor Supplements THE MARKET IS SIGNIFICANT AND LACKING & Gamble Probiotic EFFECTIVE, EVIDENCE-BASED SOLUTIONS Global Sales 2020 Market Capitalisation Current Large Market/Market Leaders $172M1 $598B For personal use only Iberogast® Bayer Gastrointestinal Supplements Germ
Slide 19: Gut Health is critical to general wellbeing
Gut Health is critical to Well-being & immune system interactions general wellbeing Maintaining gastrointestinal integrity and microbiome homeostasis can help assist autoimmune diseases by minimising dysregulation.11 A healthy gut can have other significant general benefits: Gut Brain Axis & Mental
Slide 20: Licensing discussions & portfolio diversification
Licensing discussions & portfolio diversification PROGRESSING LICENSING DISCUSSIONS WITH GLOBAL CONSUMER HEALTH COMPANIES FOR GARP GaRP 12 Months Stage 2 GaRP trial powered Revenue anticipated within 12 months from For personal use only for significance licensing Global Partners Anatara is experienc
Slide 21: Pipeline Programs including anti-obesity project
Pipeline Programs including commencement of anti-obesity project • Extensions for GaRP’s broad indications for use-trials planned for IBD paediatrics (focus on adjunctive treatment to reduce required immune suppressant dosing) & Functional Dyspepsia ( now increasingly recognised as part of the IBS s
Slide 22: Obesity is the new pandemic!
Obesity is the new pandemic! Quick Facts • In North America, more than 1 in 3 adults get the For personal use only minimum recommended physical activity each week. In Australia this is 1 in 4. • Countries with high obesity rates correlate with high sugar consumption (>50 kg per person per annum). •
Slide 23: Risks and co-morbidities associated with Obesity
Risks associated Co-morbidities associated with Obesity with Obesity 1. Increased Mortality Risk 1. Hypertension 2. Cardiovascular Risks 2. Coronary Artery Disease 3. Metabolic Risks 3. Type 2 Diabetes Mellitus 4. Respiratory Risks 4. Dyslipidemia For personal use only 5. Cancer Risks 5. Obstructive
Slide 24: Weight management and Anatara's solution
Weight management and Negative side effects compounded by weight rebound – The initial negative side effects of obesity are compounded because the physiological, metabolic, Anatara’s solution and psychological stress of rapid weight regain amplifies the initial health issues. • The risk of cardiovas
Slide 25: Obesity and GLP-1 market at a glance
Weight loss with marketed Obesity and GLP-1 market at a GLP-1 Products glance Homology with Claimed Body GLP-1 Analogue Product Name Originator Native GLP-1 Weight loss ▪ Injectables – Patient discomfort and compliance issues. Exenatide 53% Byetta / Bydureon AstraZeneca 3.5-5% ▪ Supraphysiological c
Slide 26: Contact Us
For personal use only David Brookes Dirk van Dissel Executive Chair Corporate Advisor & IR Contact Us Candour Advisory dirk@candouradvisory.com.au +61 0411 712 579 Candour Advisory Image Image Image ANATARA LIFESCIENCES LTD www.anataralifesciences.com dirk@candouradvisory.com.au
Slide 27: Advisory Board & DSMB members
Advisory Board & DSMB members ANATARA LIFESCIENCES IS SUPPORTED BY A HIGHLY ACCLAIMED ADVISORY BOARD WITH SIGNIFICANT EXPERIENCE IN GASTROINTESTINAL HEALTH. For personal use only Advisory Board members are internationally recognised for their expertise in IBS and IBD with experience ranging from pre
Slide 28: Significant Corporate Interest
Significant Corporate Interest GLOBAL TREND OF RESEARCH & DEVELOPMENT IN GASTROINTESTINAL HEALTH Several examples of investment and/or collaboration by industry leaders in gastrointestinal health For personal use only Company #1 Stock Details Company #2 Stock Details Rationale of Deal Agreement Furt
Slide 29: Corporate/PE/VC Interest
Corporate/PE/VC Interest SIGNIFICANT CORPORATE INTEREST IN THE WELLNESS AND GUT HEALTH SECTORS Corporate Interest in the Wellness space Acquirer Stock Details Target Stock Details Rationale of Deal Agreement TYO: 2503 Japanese brewer Kirin acquired Australian vitamins maker Blackmores to MKT CAP: AS
Slide 30: Peer Comparison
Peer Comparison Market Share Cash Receipts Net Operating Cash Company Stock Code Company Focus Capitalisation* Price* (FY24) (FY24) Anatara is focused on the validation of gastrointestinal Anatara ANR:ASX products including the clinical validation of GaRP, aimed at $11.6m $0.056 Nil ($1.45m) Lifesci
Slide 31: What is the gut-brain connection?
What is the gut-brain connection? PATHWAYS BETWEEN THE GUT MICROBIOTA AND THE BRAIN, FEATURING A RANGE OF GUT MOLECULES 1. The gastrointestinal system offers an integrated interface for regulation of various body functions in health and disease. 2. The lining of the gut, known as the epithelium, is
Slide 32: Pathophysiology
Pathophysiology ▪ By definition, no structural abnormalities explain Functional Gastrointestinal Disorders (FGIDs) and, on the basis of the biopsychosocial model developed by Engel 34 and adapted by Drossman,35,36 they are characterised as complex bidirectional dysregulations of gut–brain interactio
Slide 33: References
1 Appleton J. The Gut-Brain Axis: Influence of Microbiota on Mood and Mental Health. Integrative Medicine 2018; 17(4):28-32 2 Clapp M, Aurora N, Herrera L, Bhatia M, Wilen E, Wakefield S. Gut Microbiota’s Effect on Mental Health: The Gut-Brain Axis. Clinics and Practice. 2017; 7(4):987. https://doi.
Slide 34: Glossary
Glossary Irritable bowel syndrome (IBS) is a condition that affects the colon (also referred to as “large bowel” or “large intestine”). Key symptoms include abdominal pain or IBS discomfort, bloating, and chronic diarrhoea or constipation, or alternating between the two. Inflammatory bowel diseases
Anatara Lifesciences — Investor Presentation (December 2024) on 6ix